Search

In this research, two new series of N‐arylsulfonyl hydrazone compounds (14–25) possessing a sulfonate moiety were synthesized and characterized by elemental analysis and various spectroscopic techniques including fourier transform infrared (FT‐IR), 1H‐, and 13C nuclear magnetic resonance (NMR). These compounds synthesized as target molecules (14–25) were tested for their in vitro acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) inhibition activities and antioxidant potential. The antioxidant capacities of the tested molecules were determined by four different assays. The IC50values of the screened molecules were determined in the range of 60.14 ± 0.25–84.81 ± 1.09 μM against AChE and in the range of 70.11 ± 0.67–93.60 ± 0.47 μM against BChE. In the AChE assay, 4‐hydroxybenzaldehyde‐based compound 25(60.14 ± 0.25 μM) showed the highest activity in comparison to rivastigmine (501 ± 3.08 μM). This compound (71.42 ± 0.19 μM) is also one of the compounds with the highest activity against BChE. In the BChE assay, 2‐hydroxybenzaldehyde‐based compound 19(70.11 ± 0.67 μM) indicated the highest activity in comparison to rivastigmine (19.95 ± 0.20 μM). In antioxidant activity studies, the tested molecules showed lower activities than the standard compounds (butylated hydroxytoluene and α‐tocopherol). Consequently, some novel compounds can be used as potential inhibitor candidates in future studies. In this research, two new series of N‐arylsulfonyl hydrazone compounds (14–25) derived from 4‐acetamidobenzenesulfonyl hydrazide (1) were synthesized and characterized by elemental analysis and various spectroscopic techniques including fourier transform infrared (FT‐IR), 1H‐, and 13C nuclear magnetic resonance (NMR). All synthesized hydrazone compounds as target molecules (14–25) were tested for their in vitro acetylcholinesterase and butyrylcholinesterase inhibition activities and antioxidant potential.

In this study, some pyrazolone‐based Schiff base derivatives 2a‐e(except 2a) were synthesized for the first time and structurally illuminated by some spectroscopic techniques (1H, 13C NMR, FT‐IR) and elemental analysis. All synthesized molecules were screened for their anticancer and antioxidant activities, as well as AChE, BChE, and tyrosinase inhibitory properties. The obtained results exhibited that compounds 1b(IC50= 9.497 μΜ) and 2a(IC50= 30.49 μΜ) significantly decreased the proliferation of HeLa cells. On the other hand, the apoptotic effects of these two compounds were investigated with acridine orange/propidium iodide double staining. The apoptotic cell ratios of the molecules treated with these two compounds were determined as 60 and 64%. Compound 2b(IC50= 17.95 ± 0.47 μΜ) was determined to be a very active substance in the ABTS assay. Compound 2e(A0.5= 43.75 ± 0.62 μM) indicated the closest antioxidant activity to the standard compound α‐TOC (A0.5= 50.58 ± 0.39 μM) in the cupric reducing antioxidant capacity (CUPRAC) assay. In inhibition studies of enzymes, it was determined that compound 2chad a very active molecule in AChE, BChE, and tyrosinase inhibitory activities with 82.79 ± 1.03, 91.39 ± 1.06, and 92.60 ± 1.80% inhibition, respectively. It was determined that the target molecules 2a‐eshowed better antioxidant and enzyme inhibitory activities than those of ester derivatives 1a‐e. In this study, some Schiff base derivatives 2a‐e(except 2a) were synthesized for the first time, characterized by elemental analysis and some spectroscopic techniques. It was determined that some of the synthesized Schiff base derivatives had significant inhibitory activities against AChE, BChE, and tyrosinase enzymes. Also it was found that these molecules have both antioxidant and anticancer activities.